Indegene

Indegene subsidiary acquires UK firm Warn and Co for GBP 3 million

Indegene acquires US-based BioPharm for up to USD 106 million

Indegene partners with FAST India to boost India’s biotech ecosystem

Indegene partners with Indian Institute of Cerebral Palsy to support disability inclusion

Indegene expands European presence with new center in London

Indegene launches Cortex for life sciences industry

Indegene expands footprint in Europe with new entity in Spain

Indegene Q3FY25 results: Revenue rises 7% YoY to Rs 720 crore, net profit up 11% to Rs 110 crore

For the quarter ending December 31, 2024, Indegene posted a consolidated net profit of ₹110 crore, compared to ₹99 crore in Q3 FY24.

Indegene partners with CliniOps to transform clinical trial operations

Indegene shares fall nearly 7% after 4.7% equity worth Rs 707 crore changes hands in large block deal

Indegene launches new center in Hyderabad to expands global delivery network

Indegene shares surge nearly 2% as IIFL sets target price of ₹750 with ‘Add’ rating

Nomura initiates coverage on Indegene, expects stock to rally to upto Rs 700

Nomura has initiated coverage on Indegene, assigning a "Neutral" rating and setting a target price of Rs 700, citing the company's scalable business model and strong domain expertise as key strengths.

JPMorgan initiates coverage on Indegene, sets share price target at Rs 570

JPMorgan has initiated coverage on Indegene, assigning a "Neutral" rating with a target price of ₹570 per share.